bimekizumab
ucb pharmaceuticals,ucb
['be complete', ' psa', 'bimekizumab', '#1599']
merola et al. be complete study bimekizumab (il17a/fi) in tnf-ir psa. all skin and joint efficacy endpoints met. no new safety signals #acr22 abstr#1599 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC